3.08

2.33% 0.07

After Hours: 3.09 0.010 +0.32%

Pliant Therapeutics Inc (PLRX)

Overview News Price History Option Chain Financials Discussions Forecast

Pliant Therapeutics Inc stock is traded at $3.08, with a volume of 2.08M. It is up +2.33% in the last 24 hours and down -72.18% over the past month. Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Previous Close:

$3.01

Open:

$3.05

24h Volume:

2.08M

Relative Volume:

1.60

Market Cap:

$187.43M

Revenue:

$5.03M

Net Income/Loss:

$-185.41M

P/E Ratio:

-0.9968

EPS:

-3.09

Net Cash Flow:

$-139.79M

1W Performance:

+1.32%

1M Performance:

-72.18%

6M Performance:

-77.03%

1Y Performance:

-80.57%

1-Day Range:

$2.995

$3.13

1-Week Range:

$2.92

$3.22

52-Week Range:

$2.43

$18.00

Pliant Therapeutics Inc Stock (PLRX) Company Profile

Name

Pliant Therapeutics Inc

Sector

Healthcare (1169)

Industry

Biotechnology (678)

Phone

650-481-6770

Address

331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA

Employee

166

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

PLRX's Discussions on Twitter

Compare PLRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PLRX Pliant Therapeutics Inc	3.08	187.43M	5.03M	-185.41M	-139.79M	-3.09
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-10-25	Downgrade	Canaccord Genuity	Buy → Hold
Feb-10-25	Downgrade	Citigroup	Buy → Neutral
Feb-10-25	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-10-25	Downgrade	JP Morgan	Overweight → Neutral
Feb-10-25	Downgrade	Oppenheimer	Outperform → Perform
Feb-10-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Feb-10-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-09-24	Resumed	Leerink Partners	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
May-18-23	Initiated	Canaccord Genuity	Buy
Apr-13-23	Initiated	Robert W. Baird	Outperform
Dec-14-22	Initiated	Stifel	Buy
Dec-07-22	Initiated	JP Morgan	Overweight
Sep-01-22	Initiated	Citigroup	Buy
Jul-20-22	Initiated	SVB Leerink	Outperform
May-25-22	Initiated	Cantor Fitzgerald	Overweight
Dec-10-21	Initiated	Oppenheimer	Outperform
Nov-24-21	Initiated	RBC Capital Mkts	Outperform
Nov-03-21	Initiated	H.C. Wainwright	Buy
Apr-20-21	Initiated	BTIG Research	Buy
Apr-05-21	Initiated	Citigroup	Buy
Jun-29-20	Initiated	Citigroup	Buy
Jun-29-20	Initiated	Cowen	Outperform
Jun-29-20	Initiated	Needham	Buy
Jun-29-20	Initiated	Piper Sandler	Overweight

View All

Pliant Therapeutics Inc Stock (PLRX) Latest News

02:18 AM

Levi & Korsinsky Reminds Shareholders of an Investigation into Pliant Therapeutics, Inc. (PLRX) Regarding Potential Securities Fraud Allegations - ACCESS Newswire

02:18 AM

Feb 21, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Investors to Connect - Markets Insider

Feb 21, 2025

Pliant Therapeutics (PLRX) to Release Quarterly Earnings on Tuesday - MarketBeat

Feb 21, 2025

Feb 20, 2025

PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire

Feb 20, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Stockholders to Inquire about Securities Investigation - Markets Insider

Feb 20, 2025